High levels of latent antithrombin in plasma from patients with antithrombin deficiency

Summary

Antithrombin is an anticoagulant serpin that efficiently inhibits multiple procoagulant proteases. The cost for the structural flexibility required for this function is the vulnerability to mutations that impact its folding pathway. Most conformational mutations identified in serpins cause polymerisation. Only three mutations in SERPINC1 affecting two residues have been found to favour transformation to the latent conformation of antithrombin, another hyperstable non-anticoagulant form with strong antiangiogenic activity that constitutes 3 % of plasma antithrombin in healthy subjects. The analysis of latent antithrombin in 141 unrelated patients with antithrombin deficiency carrying 89 different SERPINC1 mutations identified four cases with higher levels than that of controls: p.Pro439Thr, p.Pro461Ser, p.Met283Val, and p.His401Tyr, the last also with circulating polymers. Heating of plasma at 42°C exacerbated the transformation to the latent conformation in p.Pro439Thr and p.Pro461Ser. The conformational effect of p.Met283Val, the mutation associated with the highest levels of latent antithrombin detected in four members of a family, was verified in a recombinant model. Antithrombin deficiency in these cases should be classified as pleiotropic based on the impaired reactivity and low heparin affinity of the variant. Despite high levels of latent antithrombin (up to 80 μg/ml in p.Met283Val carriers), no vascular defects were described in carriers of these mutations. In conclusion, our study identifies new residues involved in the structural stability of antithrombin (and potentially of all serpins). High levels of endogenous latent antithrombin seem to play a minor antiangiogenic effect. Finally, pleiotropic deficiencies may be caused by mutations inducing transformation to the latent conformation.

Keywords

Antithrombin - thrombosis - gene mutations - latent

• References

• 1 Bjork I, Olson ST. Antithrombin. A bloody important serpin. Adv Exp Med Biol 1997; 425: 17-33.
• 2 Aguila S, Navarro-Fernandez J, Bohdan N. et al. Role of the C-sheet in the maturation of N-glycans on antithrombin: functional relevance of pleiotropic mutations. J Thromb Haemost 2014; 12: 1131-1140.
• 3 Lane DA, Olds RJ, Conard J. et al. Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest 1992; 90: 2422-2433.
• 4 Lane DA, Olds RJ, Boisclair M. et al. Antithrombin III mutation database: first update. For the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1993; 70: 361-369.
• 5 Huntington JA. Serpin structure, function and dysfunction. J Thromb Haemost 2011; 09 (Suppl. 01) 26-34.
• 6 Whisstock JC, Bottomley SP. Molecular gymnastics: serpin structure, folding and misfolding. Curr Opin Struct Biol 2006; 16: 761-768.
• 7 Stein PE, Carrell RW. What do dysfunctional serpins tell us about molecular mobility and disease?. Nat Struct Biol 1995; 02: 96-113.
• 8 Roussel BD, Irving JA, Ekeowa UI. et al. Unravelling the twists and turns of the serpinopathies. FEBS J 2011; 278: 3859-3867.
• 9 Carrell RW, Stein PE, Fermi G. et al. Biological implications of a 3 A structure of dimeric antithrombin. Structure 1994; 02: 257-270.
• 10 Mushunje A, Evans G, Brennan SO. et al. Latent antithrombin and its detection, formation and turnover in the circulation. J Thromb Haemost 2004; 02: 2170-2177.
• 11 Larsson H, Sjoblom T, Dixelius J. et al. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res 2000; 60: 6723-6729.
• 12 O’Reilly MS, Pirie-Shepherd S, Lane WS. et al. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999; 285: 1926-1928.
• 13 Zhang W, Chuang YJ, Swanson R. et al. Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood 2004; 103: 1185-1191.
• 14 Beauchamp NJ, Pike RN, Daly M. et al. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood 1998; 92: 2696-2706.
• 15 Bruce D, Perry DJ, Borg JY. et al. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp). J Clin Invest 1994; 94: 2265-2274.
• 16 Corral J, Hernandez-Espinosa D, Soria JM. et al. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 2007; 109: 4258-4263.
• 17 Corral J, Rivera J, Martinez C. et al. Detection of conformational transformation of antithrombin in blood with crossed immunoelectrophoresis: new application for a classical method. J Lab Clin Med 2003; 142: 298-305.
• 18 de la Morena-Barrio ME, Anton AI, Martinez-Martinez I. et al. Regulatory regions of SERPINC1 gene: Identification of the first mutation associated with antithrombin deficiency. Thromb Haemost 2012; 107: 430-437.
• 19 Martinez-Martinez I, Ordonez A, Navarro-Fernandez J. et al. Antithrombin Murcia (K241E) causing antithrombin deficiency: a possible role for altered glycosylation. Haematologica 2010; 95: 1358-1365.
• 20 Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997; 18: 2714-2723.
• 21 Zhou A, Huntington JA. Carrell RW. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood 1999; 94: 3388-3396.
• 22 Chang JY, Tran TH. Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. J Biol Chem 1986; 261: 1174-1176.
• 23 Picard V, Bura A, Emmerich J. et al. Molecular bases of antithrombin deficiency in French families: identification of seven novel mutations in the antithrombin gene. Br J Haematol 2000; 110: 731-734.
• 24 Millar DS, Wacey AI, Ribando J. et al. Three novel missense mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis. Hum Genet 1994; 94: 509-512.
• 25 Irving JA, Pike RN, Lesk AM. et al. Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res 2000; 10: 1845-1864.
• 26 Olds RJ, Lane DA, Caso R. et al. Antithrombin III Budapest: a single amino acid substitution (429Pro to Leu) in a region highly conserved in the serpin family. Blood 1992; 79: 1206-1212.
• 27 Sas G, Blasko G, Banhegyi D. et al. Abnormal antithrombin III (antithrombin III “Budapest”) as a cause of a familial thrombophilia. Thromb Diath Haemorrh 1974; 32: 105-115.
• 28 Bock SC, Marrinan JA. Radziejewska E. Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochemistry 1988; 29: 6171-6178.
• 29 Picard V, Nowak-Gottl U, Biron-Andreani C. et al. Molecular bases of antithrombin deficiency: twenty-two novel mutations in the antithrombin gene. Hum Mutat 2006; 27: 600.
• 30 Luxembourg B, Delev D, Geisen C. et al. Molecular basis of antithrombin deficiency. Thromb Haemost 2011; 105: 635-646.
• 31 Navarro-Fernandez J, de la Morena-Barrio ME, Padilla J, Miñano A, Bohdan N, Aguila S. et al. Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate risk of thrombosis that causes a transient antithrombin deficiency. Thromb Haemost. In press 2016
• 32 Corral J, Vicente V. Carrell RW. Thrombosis as a conformational disease. Haematologica 2005; 90: 238-246.
• 33 Corral J, Huntington JA, Gonzalez-Conejero R. et al. Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. J Thromb Haemost 2004; 02: 931-939.
• 34 Quinsey NS, Fitton HL, Coughlin P. et al. Introduction of a mutation in the shutter region of antithrombin (Phe77 --> Leu) increases affinity for heparin and decreases thermal stability. Biochemistry 2003; 42: 10169-10173.
• 35 Chandrasekhar K, Ke H, Wang N. et al. Cellular folding pathway of a metastable serpin. Proc Natl Acad Sci USA 2016; 113: 6484-6489.
• 36 Yamasaki M, Li W, Johnson DJ. et al. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerisation. Nature 2008; 455: 1255-1258.
• 37 Kim JH, Scialli AR. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 2011; 122: 1-6.